Dr. Momoyama is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1801 S Highland Ave
Ste 130
Lombard, IL 60148Phone+1 630-627-4722
Summary
- Yoko Momoyama, MD, based in Lombard, IL, is an Internal Medicine specialist with subspecialities in Geriatric Medicine, Hospice & Palliative Medicine, and Women's Health. She completed her residency in Internal Medicine at Mount Auburn Hospital after graduating from New York Medical College in 1996. Dr. Momoyama's clinical experience includes conditions such as stable angina, heart failure, emphysema, diabetes mellitus, and osteoporosis. She has published work in Developmental Biology and has been involved in clinical trials, notably the TRAILBLAZER-ALZ 3 Alzheimer's Disease study. Dr. Momoyama's exceptional contributions to the field have been recognized with the CMS Meaningful Use Stage 1 Certification, the Patient-Centered Medical Home Recognition Program, and the Physician Practice Connections Recognition Program.
Education & Training
- Mount Auburn HospitalResidency, Internal Medicine, 1996 - 1999
- New York Medical CollegeClass of 1996
Certifications & Licensure
- AZ State Medical License 1999 - Present
- IL State Medical License 2001 - 2026
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2011-2014
Clinical Trials
- A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) Start of enrollment: 2024 Apr 30
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Start of enrollment: 2024 Jan 10
Publications & Presentations
PubMed
- 9 citationsG-actin pool and actin messenger RNA during development of the apical processes of the retinal pigment epithelial cells of the chick.V.T. Nachmias, N. Philp, Y. Momoyama, John K. Choi
Developmental Biology. 1992-02-01
Professional Memberships
- Member
Other Languages
- Japanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: